Tricom (** Experimental/Investigational (no approved brand names - studied under research protocols) **)
Inmunoterapia
Description
TRICOM is under investigation as an immunotherapy for colorectal cancer and has been studied primarily in patients with advanced or metastatic disease. It aims to enhance the immune response against tumor cells expressing specific antigens; however, its efficacy compared to standard treatments remains uncertain due to ongoing clinical trials.
Mechanism of Action
TRICOM is an experimental cancer vaccine designed to stimulate the immune system against colorectal cancer cells by targeting multiple tumor-associated antigens.
Side Effects
Fatigue; fever; chills; nausea; injection site reactions; flu-like symptoms
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00027534
Phase 1
Archived
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
United States